Search results
Results from the WOW.Com Content Network
Patented Medicine Prices Review Board office in Ottawa. Bill C-22, which was passed in 1987, established a compulsory licensing system under which drug patent holders were required to allow competing drug manufacturers to import their patented drug in exchange for a very modest 4% royalty, which resulted in an increase in the market share of generic drugs.
In Canada, the medication pricing is overseen by the Patented Medicine Prices Review Board (PMPRB), which monitors the prices set for patented drugs. [62] One way the PMPRB evaluates whether drug pricing by patentees is excessive by considering international drug pricing. [63] The PMPRB also compares the price of the drug to a similar market. [64]
In Canada, the Patented Medicine Prices Review Board (PMPRB) determines a maximum price for all drugs. In 1987, Bill C-22 established an extended period of protection for patents prior to licensing, which would allow for generics to enter the market.
1 Main Discussion of the PMPRB Article. 5 comments. ... 3 Patented Medicine Prices Review Board. 4 Not Much of An Article, Is It? 5 Administrators: Do NOT Delete.
The Canadian Patented Medicine Prices Review Board also has the authority to set a fair and reasonable price on patented products, either comparing it to similar drugs already on the market, or by taking the average price in seven developed nations. [101] [102] Prices are also
The World Health Organization and Health Action International (WHO/HAI) made a conjoint effort to systematize the methodology of medicine price surveys and ERP usage, first publishing the WHO/HAI methodology in manual in 2003, [3]: 195 which is frequently used in price studies in unregulated prices context often found in low and moderate income ...
A portion of the disclosure of this patent document contains material which is subject to (copyright or mask work) protection. The (copyright or mask work) owner has no objection to the facsimile reproduction by anyone of the patent document or the patent disclosure, as it appears in the Patent and Trademark Office patent file or records, but ...
The Drug Price Competition and Patent Term Restoration Act (Public Law 98-417), informally known as the Hatch-Waxman Act, is a 1984 United States federal law that established the modern system of generic drug regulation in the United States.